Domínguez GEJ, Navarro FF, Navarro SP

Language: Spanish
References: 25
Page: 1007-1016
PDF size: 74.88 Kb.

ABSTRACT

Hepatic metastasis is frequent in the course of diverse primary tumors and, sometimes, this it is the first in being diagnosed. Achieving a precise description of the metastatic liver from the functional and anatomical point of view is indispensable to indicate an opportune treatment. On the base of these statements, some aspects related to the main diagnosis means used in patients with this morbid process are exposed.

REFERENCES

1. Martínez CJ, Jarufe CN, González DR, Álvarez ZM. Alternativas terapéuticas actuales de las metástasis hepáticas. Rev Méd Chile. 2008 [citado 14 Feb 2016];136:376-84. Disponible en: http://dx.doi.org/10.4067/S0034-98872008000300015

2. Senra Armas LA, Andara Ramírez MT, Noa Pedroso G. Metástasis hepática como forma de presentación de cáncer. Rev Cubana Med. 2015 [citado 14 Feb 2016]; 54(1). Disponible en: http://www.bvs.sld.cu/revistas/med/vol_54_1_15/med04115.htm

3. Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology. 2013;266(2):407-30.

4. Pincus MR, Abraham NZ. Interpreting laboratory results. In: McPherson RA, Pincus MR. Henry's clinical diagnosis and management by laboratory methods. 22th. Philadelphia: Elsevier Saunders; 2011.

5. Menéndez Sánchez P, Villarejo Campos P, Menéndez Rubio JM, Rodríguez Montes JA, Padilla Valverde D. Marcadores tumorales en el cáncer colorrectal. Cirugía y Cirujanos. 2013 [citado 14 Feb 2016];81(2). Disponible en: http://redalyc.org/articulo.oa?id=66225687016

6. Dong Y, Wu WK, Wu CW, Sung JJ, Yu J, Ng SS. MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br J Cancer. 2011;104(6):893-8.

7. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6(3):17745.

8. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn. 2011;11(3):259-75.

9. Nugent M, Miller N, Kerin MJ. MicroRNAs in colorectal cancer: function, dysregulation and potential as novel biomarkers. Eur J Surg Oncol. 2011;37(8):649-54.

10. Roa I, Sánchez T, Majlis A, Schalper K. Mutación del gen KRAS en el cáncer de colon y recto. Rev Méd Chile. 2013 [citado 14 Feb 2016];141(9). Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000900009

11. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18(8):2257-68.

12. Itzkowitz SH, Potack J. Colonic polyps and polyposis syndromes. In: Feldman M, Friedman LS, Brandt LJ. Sleisenger and fordtran's gastrointestinal and liver disease pathophysiology/diagnosis/management. 9th. Philadelphia: Elsevier Saunders; 2010.

13. Palma RM, Bielsa S, Panadés MJ, Pardina M, Porcel JM. Rentabilidad diagnóstica de la punción aspiración con aguja fina para citología en lesiones hepáticas multifocales: comparación entre la punción a ciegas vs la dirigida por imagen. Rev Clin Esp. 2013;213(9):435-9.

14. Garrett R. Solid liver masses: approach to management from the standpoint of a radiologist. Curr Gastroenterol Rep. 2013;15(12):359.

15. Sandrasegaran K. Functional imaging of the abdomen. Radiol Clin North Am. 2014;52:883–903.

16. Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment and treatment. Curr Probl Diagn Radiol. 2015;44(6):479-86.

17. Tang A, Cruite I, Sirlin CB. Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol. 2013;7(3):269-79.

18. Vilgrain V, Van Beers BE, Pastor CM. Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. J Hepatol 2016;64(3):708-16.

19. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43.

20. Vallejo Desviat P, Martínez de Vega V, Recio Rodríguez M, Jiménez de la Peña M, Carrascoso Arranz J. Difusión en resonancia magnética en el estudio de lesiones hepáticas. Cir Española. 2013 [citado 14 Feb 2016];91(1). Disponible en: http://www.elsevier.es/es-revista-cirugia-espanola-36-articulo-difusion-resonanciamagnetica- el-estudio-90185122

21. Kamimura K, Nagamachi S, Wakamatsu H, Higashi R, Ogita M, Ueno S, et al. Associations between liver 18F fluoro-2-deoxy-D-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome. Ann Nucl Med. 2010;24:157-61.

22. Batallés SM, Villavicencio RL, Quaranta A, Burgos L, Trezzo S, Staffieri RV. Variaciones del SUV hepático con relación al índice de masa corporal en estudios PET/TOMOGRAFÍA de cuerpo entero. Rev Esp Med Nucl Imagen. 2013 [citado 14 Feb 2016];32(1). Disponible en: http://www.elsevier.es/es-revista-revista-espanolamedicina- nuclear-e-125-articulo-variaciones-del-suv-hepatico-con-90180963

23. Seo HJ, Kim MJ, Lee JD, Chung WS, Kim YE. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol. 2011;46:548-55.

24. Jiménez Román JA, Costa Fernández C, Lozano Calero K, Machán F, Fernández Gutiérrez A, Rebollo García N. Volumetría hepática por tomografía en la valoración prequirúrgica del hígado. Radiol. 2014;56:342.

25. Moreira VF, Garrido E. Elastografía hepática (Fibroscan®) en hepatología. Rev Esp Enferm Dig. 2013 [citado 14 Feb 2016];105(4). Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000400011